# A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer

> **NCT02973737** · PHASE3 · UNKNOWN · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 279 (actual)

## Conditions studied

- HER2 Positive Metastatic Breast Cancer

## Interventions

- **DRUG:** pyrotinib
- **DRUG:** placebo
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT02973737
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-07-20
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 279 (ACTUAL)
- **Last updated:** 2022-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02973737

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02973737, "A Study of Pyrotinib Plus Capecitabine in Patients With HER2+ Metastatic Breast Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02973737. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*